K

Kodiak Sciences Inc. (KOD)

NGM – Real vaqt narxi. Valyuta: USD

39.49

-0.36 (-0.90%)

Yopilishda: May 12, 2026, 4:00 PM EDT

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Barcha huquqlar himoyalangan.

Foydalanish shartlari

K

Kodiak Sciences Inc. (KOD)

NGM – Real vaqt narxi. Valyuta: USD

39.49

-0.36 (-0.90%)

Yopilishda: May 12, 2026, 4:00 PM EDT

08.05.2026

Kodiak's Q1 Loss Wider Than Expected, Pipeline Development in Focus

KOD posts a wider Q1 loss as research & development spending rises, while positive phase III Zenkuda data accelerate the regulatory plans.

07.05.2026

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results

PALO ALTO, Calif., May 7, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ended March 31, 2026.

01.05.2026

Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences

Clinical results of KSI-101 in macular edema secondary to inflammation (MESI) from a tertiary care uveitis practice demonstrate outcomes consistent with results from the U.S. Phase 1b APEX study, supporting continued global development and expansion of the Phase 3 PEAK and PINNACLE program into Asia. Ongoing advancement of bispecific therapies in geographic atrophy and ocular inflammatory disease; preclinical data continue to support a multi-target approach to address limitations of current single-target therapies.

30.04.2026

Kodiak Sciences (KOD) Up 2% Since Last Earnings Report: Can It Continue?

Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock?

01.04.2026

Kodiak Q4 Loss Wider Than Expected, Pipeline Development in Focus

KOD posts wider Q4 loss. However, its pipeline advances, with strong phase III data for Zenkuda driving accelerated regulatory plans.

31.03.2026

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

PALO ALTO, Calif., March 31, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2025.

30.03.2026

Kodiak Sciences: Road To $120

Kodiak Sciences' stock (NASDAQ: KOD) experienced a substantial 62% surge last week, elevating the stock to $37 and increasing its market capitalization to $2.3 billion. This impressive momentum was fueled by robust Phase 3 GLOW2 results for Zenkuda (tarcocimab), an experimental treatment aimed at retinal vascular disorders.

Videolar

31.10.2025

Positive

The Big 3: GOOGL, KOD, FTK

Press-relizlar

07.05.2026

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results

PALO ALTO, Calif., May 7, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ended March 31, 2026.

31.03.2026

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

PALO ALTO, Calif., March 31, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2025.

26.03.2026

Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham

Building on the success of GLOW1 and with all patients on a 6-month dosing interval, Zenkuda (tarcocimab tedromer) demonstrated superiority to sham with 62.5% of Zenkuda-treated patients achieving a ≥2-step improvement in diabetic retinopathy severity score (DRSS) compared to 3.3% of sham-treated patients (p

04.02.2026

Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026

PALO ALTO, Calif., Feb. 4, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today participation at the virtual Angiogenesis (Angiogenesis, Exudation, and Degeneration) annual meeting on February 7, 2026.

Search stocks

Kodiak Sciences Inc. (KOD)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Kodiak Sciences Inc. (KOD)

Kodiak's Q1 Loss Wider Than Expected, Pipeline Development in Focus

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results

Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences

Kodiak Sciences (KOD) Up 2% Since Last Earnings Report: Can It Continue?

Kodiak Q4 Loss Wider Than Expected, Pipeline Development in Focus

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

Kodiak Sciences: Road To $120

Videolar

Press-relizlar

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham

Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026